Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
Diseases of the Musculoskeletal System | Diseases of the Nervous System
What is the purpose of this trial?
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG). Subjects will be randomized in a 1:1:1 ratio to receive daily SC doses of 0.1 mg/kg RA101495, 0.3 mg/kg RA101495, or matching placebo for 12 weeks.
- Ages18 years - 85 years
- Trial withRa Pharmaceuticals, Inc.
- Start Date04/19/2018
- End Date12/30/2018
- Last Updated05/07/2018
- Study HIC#2000021849